Combining a newer generation PTC readthrough aminoglycoside derivative such as NB124 with an approved enhancer like mefloquine has potential to generate sufficient functional readthrough TP53 to achieve a therapeutic effect in cancer. This evidence concerns the gene TP53 and cancer.